Phase III clinical study of DQ-2466 -Double-blind controlled study of fixed-dose and up-titration DQ-2466 regimens in subjects with persistent or permanent atrial fibrillation -

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222155

Enrollment

120

Registered

2013-07-26

Start date

2013-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent or permanent atrial fibrillation

Interventions

investigational material(s) Generic name etc : DQ-2466 INN of investigational material : Carvedilol Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed as persistent or permanent atrial fibrillation and have excessive mean heart rate above 80 beats per minute on Holter ECG.

Exclusion criteria

Exclusion criteria: .Patients who recently took a beta-blocker or a calcium antagonist (e.g., diltiazem or verapamil) .Patients receiving treatment for heart failure (NYHA classes II to IV). .Patients with contraindication of carvedilol therapy. .Patients with poorly controlled diabetes mellitus or hypertension. .Patients with hepatic or renal impairment.

Design outcomes

Primary

Measure	Time frame
Efficacy endpoints (24-hour mean heart rate measured by Holter ECG) Safety endpoints (adverse events, laboratory tests, blood pressure, 12-lead ECG findings).	—

Secondary

Measure	Time frame
The change of heart rate on the 12-lead ECG.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026